ZS Pharma (ZSPH +3.4%) completes enrollment in a Phase 3 clinical trial of ZS-9 (sodium zirconium cyclosilicate) for hyperkalemia. The 258-patient study is a randomized, double-blind, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback